Active, Not Recruiting
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) - CA209-370
Updated: 1 July, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologically confirmed locally advanced or stage IV NSCLC - Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2 - Tumor tissue sections must be available for biomarker evaluation Exclusion Criteria: - Untreated or active/progressing Central Nervous system (CNS) metastases - Active, known or suspected autoimmune disease - Known history of testing positive for HIV or AIDS - Active or chronic infection of hepatitis B virus or hepatitis C
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information